Barclays’s Rapport Therapeutics RAPP Stock Holding History

Barclays’s Portfolio RAPP Stock Details RAPP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$625K	Buy	14,994 +5,383	+56%	+$198K	﹤0.01%	3093
2026 Q1	$301K	Sell	9,611 -42,869	-82%	-$1.21M	﹤0.01%	3471
2025 Q4	$1.59M	Buy	52,480 +25,767	+96%	+$713K	﹤0.01%	3095
2025 Q3	$793K	Sell	26,713 -44,395	-62%	-$792K	﹤0.01%	3514
2025 Q2	$808K	Buy	71,108 +8,412	+13%	+$89.3K	﹤0.01%	3477
2025 Q1	$629K	Buy	62,696 +44,199	+239%	+$574K	﹤0.01%	3383
2024 Q4	$328K	Buy	18,497 +5,634	+44%	+$125K	﹤0.01%	4068
2024 Q3	$263K	Buy	12,863 +3,463	+37%	+$74.4K	﹤0.01%	4151
2024 Q2	$219K	Buy	+9,400	New	+$218K	﹤0.01%	3531

Other funds holding RAPP

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TGV

TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Barclays's RAPP Position: Q2 2026 in Review

Barclays increased its Rapport Therapeutics (RAPP) stake by 56% in Q2 2026, buying an estimated $198K and bringing the position to 14,994 shares worth $625K. The position accounts for ﹤0.01% of the portfolio, ranked #3093.

Barclays first reported a position in RAPP in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.59M in Q4 2025. 160 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

Barclays held 14,994 shares of Rapport Therapeutics worth $625K as of Q2 2026.
Barclays bought 5,383 Rapport Therapeutics shares in Q2 2026, an estimated $198K.
Rapport Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3093 holding.
Barclays first reported a position in Rapport Therapeutics in Q2 2024 and has held it in 9 quarters since.
Barclays's Rapport Therapeutics position peaked at $1.59M in Q4 2025.
160 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.